JP2024534824A - 操作された抗ｈｅｒ２二重特異性タンパク質 - Google Patents

操作された抗ｈｅｒ２二重特異性タンパク質 Download PDF

Info

Publication number
JP2024534824A
JP2024534824A JP2024511978A JP2024511978A JP2024534824A JP 2024534824 A JP2024534824 A JP 2024534824A JP 2024511978 A JP2024511978 A JP 2024511978A JP 2024511978 A JP2024511978 A JP 2024511978A JP 2024534824 A JP2024534824 A JP 2024534824A
Authority
JP
Japan
Prior art keywords
sequence
seq
polypeptide
substitution
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024511978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534824A5 (OSRAM
Inventor
アビラ ボンドパッダエ
アリサ ジェーン クレメンス
ド ジン キム
ミシェル イー． ピゾ
ルー シャン
ジュニア リチャード セオリス
レイモンド カ ハン トン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of JP2024534824A publication Critical patent/JP2024534824A/ja
Publication of JP2024534824A5 publication Critical patent/JP2024534824A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024511978A 2021-08-25 2022-08-25 操作された抗ｈｅｒ２二重特異性タンパク質 Pending JP2024534824A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163237071P 2021-08-25 2021-08-25
US63/237,071 2021-08-25
PCT/US2022/041471 WO2023038803A2 (en) 2021-08-25 2022-08-25 Engineered anti-her2 bispecific proteins

Publications (2)

Publication Number Publication Date
JP2024534824A true JP2024534824A (ja) 2024-09-26
JP2024534824A5 JP2024534824A5 (OSRAM) 2025-08-28

Family

ID=85506758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024511978A Pending JP2024534824A (ja) 2021-08-25 2022-08-25 操作された抗ｈｅｒ２二重特異性タンパク質

Country Status (5)

Country Link
US (1) US20240392035A1 (OSRAM)
EP (1) EP4392064A4 (OSRAM)
JP (1) JP2024534824A (OSRAM)
CN (1) CN118119402A (OSRAM)
WO (1) WO2023038803A2 (OSRAM)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5587975B2 (ja) * 2009-04-07 2014-09-10 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体
EP4570318A3 (en) * 2013-11-27 2025-10-15 Zymeworks BC Inc. Bispecific antigen-binding constructs targeting her2
CA2925677A1 (en) * 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Bispecific her2 antibodies and methods of use
SG11201608192SA (en) * 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
CA3109763A1 (en) * 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
EP3840781A1 (en) * 2018-08-22 2021-06-30 Denali Therapeutics Inc. Anti-her2 polypeptides and methods of use thereof
IL295729A (en) * 2020-02-19 2022-10-01 Denali Therapeutics Inc Bispecific engineered anti-2her proteins, preparations containing them and their uses

Also Published As

Publication number Publication date
US20240392035A1 (en) 2024-11-28
WO2023038803A2 (en) 2023-03-16
WO2023038803A3 (en) 2023-08-17
EP4392064A4 (en) 2025-12-24
EP4392064A2 (en) 2024-07-03
CN118119402A (zh) 2024-05-31

Similar Documents

Publication Publication Date Title
JP7818042B2 (ja) 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法
US20230192887A1 (en) Engineered anti-her2 bispecific proteins
JP7793774B2 (ja) メソテリン結合タンパク質及びその使用
CN117120478A (zh) 一种抗原结合分子
JP2025524347A (ja) ガンマデルタｔ細胞受容体に結合するバリアント抗体
US20240392035A1 (en) Engineered anti-her2 bispecific proteins
US20260109781A1 (en) Anti-her2 antibodies and methods of use thereof
HK40084724A (en) Engineered anti-her2 bispecific proteins
HK40110414A (zh) 抗her2抗体及其使用方法
WO2024193450A9 (en) Anti-b7h3 antibodies and methods of use
US20260035478A1 (en) Mesothelin binding proteins and uses thereof
JP2025525291A (ja) ガンマ－デルタｔ細胞受容体に結合する抗体を含む組成物
CN120530135A (zh) 抗b7h3抗体和使用方法
CN121293352A (zh) 抗cmet抗体及使用方法
HK40118288A (zh) 包含结合γ-δ T细胞受体的抗体的组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250820